Skip to Content
Merck

The proteome of clear cell ovarian carcinoma.

The Journal of pathology (2022-08-30)
Jennifer X Ji, Dawn R Cochrane, Gian Luca Negri, Shane Colborne, Sandra E Spencer Miko, Lynn N Hoang, David Farnell, Basile Tessier-Cloutier, Jutta Huvila, Emily Thompson, Samuel Leung, Derek Chiu, Christine Chow, Monica Ta, Martin Köbel, Lucas Feil, Michael Anglesio, Ellen L Goode, Kelly Bolton, Gregg B Morin, David G Huntsman
PMID36031730
ABSTRACT

Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease. © 2022 The Pathological Society of Great Britain and Ireland.